A new approach for the treatment of mastitis in dairy cows

Triesenberg, Liechtenstein, May 8, 2023–(BUSINESS WIRE)–Amicogen, a leading biotechnology company specializing in the industrial production of enzymes and drug development, is an innovative biotechnology company with expertise in the development of the antibacterial agent artylysin partnered with Rysand.®to address the problem of increasing mastitis in dairy cows caused by multidrug-resistant bacteria.

This press release features multimedia. Read the full release here: https://www.businesswire.com/news/home/20230508005095/en/

lab work

Recent studies show that overuse of antibiotics in animal husbandry is leading to a rapid increase in multidrug-resistant pathogens. About 70% of all antibiotics produced worldwide are used in agriculture, often as a preventive measure, accelerating the spread of resistant bacteria.

Mastitis – a bacterial infection of the breast caused by various, often multidrug-resistant bacterial strains – is spreading rapidly, especially in Asia. This leads to animal suffering and significant waste of milk production, causing the global dairy industry to lose approximately $20-30 billion annually in lost revenue.

The partnership between Amicogen and Lysando aims to develop innovative solutions to this pressing problem. By leveraging their combined expertise, the companies set out to create effective and sustainable treatments to improve animal welfare while reducing the economic impact of mastitis on farmers. .

Dr. Park, CEO of Amicogen, said: “This collaboration underscores the growing importance of working together in biotechnology and the potential for innovation to address key challenges, as well as in agriculture.”

“Our Artyricin® The technology shows great promise in tackling bacterial infections and we believe this partnership will make a real difference in the fight against mastitis,” adds Dr. Kerstin Emmrich, Director of R&D at Lysando AG. I was.

Amicogen and Lysando’s joint effort is an important step towards combating the growing problem of antibiotic resistance and improving animal health. Both companies envision continuing research to provide innovative solutions to important challenges.

About Amicogen

Amicogen Inc (092040.KQ) is a CDMO and biotechnology company based in Jinju, South Korea. Amicogen is a leader in the development and production of specialty enzymes and proteins for biopharmaceuticals, food, cosmetics and other industries.

About Lysand

Lysando AG is the market leader in antibacterial proteins, so-called Artilysin® molecule. They can effectively eliminate problem-causing bacteria without the high risk of resistance formation or microbial imbalance.Altolysin® It is an innovative, unique and environmentally friendly technology with a wide range of applications.

View source version at businesswire.com: https://www.businesswire.com/news/home/20230508005095/en/

contact address

Verena Shoosman

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *